147 related articles for article (PubMed ID: 17579978)
1. Low-dose HCG is useful in preventing OHSS in high-risk women without adversely affecting the outcome of IVF cycles.
Nargund G; Hutchison L; Scaramuzzi R; Campbell S
Reprod Biomed Online; 2007 Jun; 14(6):682-5. PubMed ID: 17579978
[TBL] [Abstract][Full Text] [Related]
2. GnRHa trigger and individualized luteal phase hCG support according to ovarian response to stimulation: two prospective randomized controlled multi-centre studies in IVF patients.
Humaidan P; Polyzos NP; Alsbjerg B; Erb K; Mikkelsen AL; Elbaek HO; Papanikolaou EG; Andersen CY
Hum Reprod; 2013 Sep; 28(9):2511-21. PubMed ID: 23753114
[TBL] [Abstract][Full Text] [Related]
3. Severe early ovarian hyperstimulation syndrome following GnRH agonist trigger with the addition of 1500 IU hCG.
Seyhan A; Ata B; Polat M; Son WY; Yarali H; Dahan MH
Hum Reprod; 2013 Sep; 28(9):2522-8. PubMed ID: 23633553
[TBL] [Abstract][Full Text] [Related]
4. Consistent high clinical pregnancy rates and low ovarian hyperstimulation syndrome rates in high-risk patients after GnRH agonist triggering and modified luteal support: a retrospective multicentre study.
Iliodromiti S; Blockeel C; Tremellen KP; Fleming R; Tournaye H; Humaidan P; Nelson SM
Hum Reprod; 2013 Sep; 28(9):2529-36. PubMed ID: 23873146
[TBL] [Abstract][Full Text] [Related]
5. A novel oocyte maturation trigger using 1500 IU of human chorionic gonadotropin plus 450 IU of follicle-stimulating hormone may decrease ovarian hyperstimulation syndrome across all in vitro fertilization stimulation protocols.
Anaya Y; Mata DA; Letourneau J; Cakmak H; Cedars MI; Rosen MP
J Assist Reprod Genet; 2018 Feb; 35(2):297-307. PubMed ID: 29086322
[TBL] [Abstract][Full Text] [Related]
6. Successful pregnancies in patients with estrogenic anovulation after low-dose human chorionic gonadotropin therapy alone following hMG for controlled ovarian hyperstimulation.
Lee KL; Couchman GM; Walmer DK
J Assist Reprod Genet; 2005 Jan; 22(1):37-40. PubMed ID: 15807221
[TBL] [Abstract][Full Text] [Related]
7. Towards an optimal luteal support modality in agonist triggered cycles: a randomized clinical trial.
Elgindy EA; Sibai H; Mostafa MI; Gibreel A; Darwish E; Maghraby H
Hum Reprod; 2018 Jun; 33(6):1079-1086. PubMed ID: 29562260
[TBL] [Abstract][Full Text] [Related]
8. Low dose human chorionic gonadotropin administration at the time of gonadotropin releasing-hormone agonist trigger versus 35 h later in women at high risk of developing ovarian hyperstimulation syndrome - a prospective randomized double-blind clinical trial.
Engmann LL; Maslow BS; Kaye LA; Griffin DW; DiLuigi AJ; Schmidt DW; Grow DR; Nulsen JC; Benadiva CA
J Ovarian Res; 2019 Jan; 12(1):8. PubMed ID: 30684970
[TBL] [Abstract][Full Text] [Related]
9. Prevention of severe ovarian hyperstimulation syndrome in IVF with or without ICSI and embryo transfer: a modified 'coasting' strategy based on ultrasound for identification of high-risk patients.
Al-Shawaf T; Zosmer A; Hussain S; Tozer A; Panay N; Wilson C; Lower AM; Grudzinskas JG
Hum Reprod; 2001 Jan; 16(1):24-30. PubMed ID: 11139531
[TBL] [Abstract][Full Text] [Related]
10. GnRH antagonist administered twice the day before hCG trigger combined with a step-down protocol may prevent OHSS in IVF/ICSI antagonist cycles at risk for OHSS without affecting the reproductive outcomes: a prospective randomized control trial.
Prapas Y; Ravanos K; Petousis S; Panagiotidis Y; Papatheodorou A; Margioula-Siarkou C; Iuliano A; Gullo G; Prapas N
J Assist Reprod Genet; 2017 Nov; 34(11):1537-1545. PubMed ID: 28776117
[TBL] [Abstract][Full Text] [Related]
11. Prediction of Ovarian Hyperstimulation Syndrome in Patients Treated with Corifollitropin alfa or rFSH in a GnRH Antagonist Protocol.
Griesinger G; Verweij PJ; Gates D; Devroey P; Gordon K; Stegmann BJ; Tarlatzis BC
PLoS One; 2016; 11(3):e0149615. PubMed ID: 26950065
[TBL] [Abstract][Full Text] [Related]
12. Risk of severe ovarian hyperstimulation syndrome in GnRH antagonist versus GnRH agonist protocol: RCT including 1050 first IVF/ICSI cycles.
Toftager M; Bogstad J; Bryndorf T; Løssl K; Roskær J; Holland T; Prætorius L; Zedeler A; Nilas L; Pinborg A
Hum Reprod; 2016 Jun; 31(6):1253-64. PubMed ID: 27060174
[TBL] [Abstract][Full Text] [Related]
13. Prevention of severe ovarian hyperstimulation syndrome (OHSS) in IVF patients by steroidal ovarian suppression--a prospective randomized study.
Schwärzler P; Abendstein BJ; Klingler A; Kreuzer E; Rjosk HK
Hum Fertil (Camb); 2003 Aug; 6(3):125-9. PubMed ID: 12960445
[TBL] [Abstract][Full Text] [Related]
14. The benefits of mid-luteal addition of human chorionic gonadotrophin in in-vitro fertilization using a down-regulation protocol and luteal support with progesterone.
Herman A; Raziel A; Strassburger D; Soffer Y; Bukovsky I; Ron-El R
Hum Reprod; 1996 Jul; 11(7):1552-7. PubMed ID: 8671503
[TBL] [Abstract][Full Text] [Related]
15. Prevention of the onset of ovarian hyperstimulation syndrome (OHSS) in the rat after ovulation induction with a low molecular weight agonist of the LH receptor compared with hCG and rec-LH.
van de Lagemaat R; Raafs BC; van Koppen C; Timmers CM; Mulders SM; Hanssen RG
Endocrinology; 2011 Nov; 152(11):4350-7. PubMed ID: 21896671
[TBL] [Abstract][Full Text] [Related]
16. Does withholding gonadotrophin administration prevent severe ovarian hyperstimulation syndrome?
Lee C; Tummon I; Martin J; Nisker J; Power S; Tekpetey F
Hum Reprod; 1998 May; 13(5):1157-8. PubMed ID: 9647538
[TBL] [Abstract][Full Text] [Related]
17. Comparison of gonadotrophin-releasing hormone analogues and human chorionic gonadotrophin for the induction of ovulation and prevention of ovarian hyperstimulation syndrome: a case-control study.
Lewit N; Kol S; Manor D; Itskovitz-Eldor J
Hum Reprod; 1996 Jul; 11(7):1399-402. PubMed ID: 8671474
[TBL] [Abstract][Full Text] [Related]
18. GnRH agonist with low-dose hCG (dual trigger) is associated with higher risk of severe ovarian hyperstimulation syndrome compared to GnRH agonist alone.
O'Neill KE; Senapati S; Maina I; Gracia C; Dokras A
J Assist Reprod Genet; 2016 Sep; 33(9):1175-84. PubMed ID: 27349252
[TBL] [Abstract][Full Text] [Related]
19. Ovarian hyperstimulation syndrome: a clinical report on 4894 consecutive ART treatment cycles.
Sousa M; Cunha M; Teixeira da Silva J; Oliveira C; Silva J; Viana P; Barros A
Reprod Biol Endocrinol; 2015 Jun; 13():66. PubMed ID: 26100393
[TBL] [Abstract][Full Text] [Related]
20. Follicular aspiration versus coasting for ovarian hyper-stimulation syndrome prevention.
Bushaqer NJ; Dayoub NM; AlHattali KK; Ayyoub HA; AlFaraj SS; Hassan SN
Saudi Med J; 2018 Mar; 39(3):290-295. PubMed ID: 29543308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
